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During inflammation, leukocytes extravasating 
from the blood into the surrounding tissue have 
to  overcome  the  endothelial  barrier  of  the 
blood vessel wall. Capture and arrest of leuko-
cytes to the luminal surface of the endothelium 
at sites of emigration requires the interplay of 
several adhesion and signaling molecules, such 
as selectins, chemokines, and integrin ligands 
(Ley et al., 2007). This is then followed by the 
actual transmigration step, a process called dia-
pedesis (Vestweber, 2007; Muller, 2009).
Several adhesion molecules at endothelial 
cell contacts, such as platelet endothelial cell ad-
hesion molecule 1 (Muller et al., 1993) and CD99 
(Schenkel et al., 2002; Bixel et al., 2004), and 
some at endothelial tight junctions, such as the 
junctional adhesion molecules (Martìn-Padura 
et  al.,  1998;  Nourshargh  et  al.,  2006)  and   
endothelial  cell–specific  adhesion  molecule 
(Wegmann et al., 2006) are known to support 
leukocyte diapedesis. The fact that they are 
located  at  the  interface  between  endothelial 
cells is a strong indication that they participate 
in  the  migration  of  leukocytes  through  the 
junctional pathway (Muller, 2001; Nourshargh 
et al., 2010). However, in vitro studies have 
shown that several of these adhesion molecules, 
particularly PECAM-1, junctional adhesion mole-
cule A, and CD99 are also found surrounding 
leukocytes that migrate through the body of an 
endothelial cell on a transcellular route (Carman 
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We have recently shown that vascular endothelial protein tyrosine phosphatase (VE-PTP), 
an endothelial membrane protein, associates with VE-cadherin and is required for optimal 
VE-cadherin function and endothelial cell contact integrity. The dissociation of VE-PTP 
from VE-cadherin is triggered by vascular endothelial growth factor (VEGF) and by the 
binding of leukocytes to endothelial cells in vitro, suggesting that this dissociation is a 
prerequisite for the destabilization of endothelial cell contacts. Here, we show that VE-
cadherin/VE-PTP dissociation also occurs in vivo in response to LPS stimulation of the lung 
or systemic VEGF stimulation. To show that this dissociation is indeed necessary in vivo for 
leukocyte extravasation and VEGF-induced vascular permeability, we generated knock-in 
mice expressing the fusion proteins VE-cadherin-FK 506 binding protein and VE-PTP-FRB* 
under the control of the endogenous VE-cadherin promoter, thus replacing endogenous  
VE-cadherin. The additional domains in both fusion proteins allow the heterodimeric com-
plex to be stabilized by a chemical compound (rapalog). We found that intravenous appli-
cation of the rapalog strongly inhibited VEGF-induced (skin) and LPS-induced (lung) 
vascular permeability and inhibited neutrophil extravasation in the IL-1 inflamed cremas-
ter and the LPS-inflamed lung. We conclude that the dissociation of VE-PTP from  
VE-cadherin is indeed required in vivo for the opening of endothelial cell contacts during 
induction of vascular permeability and leukocyte extravasation.
© 2011 Broermann et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months it 
is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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To this end, we have fused additional protein domains (FKBP 
and FRB*) to the C termini of VE-cadherin and VE-PTP, 
which contain binding sites for a small molecule called   
rapalog, allowing for stabilization of VE-cadherin/VE-PTP 
heterodimers. DNA constructs for both fusion proteins were 
knocked into the VE-cadherin locus of gene-targeted mice, 
thereby replacing endogenous VE-cadherin. We found that 
LPS-triggered leukocyte recruitment into the lung, as well 
as  i.v.  injected  VEGF,  both  stimulate  the  dissociation  of   
VE-PTP from VE-cadherin in vivo. Administering rapalog 
into the circulation prevented this dissociation and strongly 
reduced VEGF- and LPS-induced vascular permeability,   
IL-1-induced recruitment of neutrophils in the cremaster 
tissue, and LPS-induced infiltration of neutrophils into lungs. 
Thus, dissociation of VE-PTP from VE-cadherin is indeed 
necessary in vivo for the opening of endothelial cell contacts 
in both processes.
RESULTS AND DISCUSSION
Characterization of VE-cadherin-FKBP  
and VE-PTP-FRB* fusion proteins
We have recently found that two different stimuli thought to 
destabilize endothelial cell contacts, the binding of leukocytes 
to cultured endothelial cells and the growth factor VEGF, 
each stimulate the dissociation of VE-PTP from VE-cadherin 
(Nottebaum et al., 2008). To test whether this dissociation is 
required for leukocyte extravasation and induction of vascu-
lar permeability, we generated modified forms of VE-cadherin 
and VE-PTP to prevent their dissociation. The rapamycin-
binding domain of the FK 506 binding protein (FKBP) was 
fused  to  the  C  terminus  of  VE-cadherin  (VE-cadherin-
FKBP), and a mutated form of the rapamycin binding do-
main of mammalian target of rapamycin (FRB*), containing 
an HA-tag at its C terminus, was fused to the C terminus of 
VE-PTP (VE-PTP-FRB*; Fig. 1 A). Delivery of a nonimmuno-
suppressive rapamycin analogue (rapalog) that does not bind 
mammalian  target  of  rapamycin  should  simultaneously 
bind to the rapamycin domains of FKBP and FRB*, thus 
stabilizing  the  interaction  between  the  VE-cadherin  and   
VE-PTP fusion proteins.
To test whether the additional protein domains would 
affect the functions of VE-cadherin and VE-PTP, we trans-
fected the fusion proteins into COS-7 cells. As shown in 
Fig. 1 B, -catenin, plakoglobin, -catenin, and p120 catenin 
co-precipitated with VE-cadherin-FKBP in a similar man-
ner as with wild-type VE-cadherin. In addition, VE-PTP-
FRB* and VE-cadherin-FKBP interacted to the same extent 
with each other as do the corresponding wild-type proteins 
(Fig.  1  C). This  was  tested  with  the  shortened  form  of   
VE-PTP (Flag-VE-PTP) lacking the 16 N-terminal FNIII-
like  repeats  of  VE-PTP,  known  to  interact  with  VE- 
cadherin as efficiently as full-length VE-PTP (Nawroth et al., 
2002). Finally, expression of VEGF-R2 together with VE-
cadherin-FKBP in COS-7 cells resulted in tyrosine phos-
phorylation of the fusion protein similar to WT VE-cadherin 
(Fig. 1 D, lanes 2 and 4). Flag-VE-PTP-FRB* was able to 
et al., 2007; Mamdouh et al., 2009), suggesting that these ad-
hesion receptors might also participate in the transcellular diape-
desis of leukocytes.
For the paracellular route, leukocytes have to overcome 
endothelial junctions whose opening and closure needs to be 
tightly controlled to facilitate extravasation and avoid leakage 
(Vestweber et al., 2009; Nourshargh et al., 2010). VE-cadherin 
is of major importance to the integrity of endothelial cell con-
tacts (Breviario et al., 1995; Matsuyoshi et al., 1997; Crosby   
et al., 2005). Antibodies against VE-cadherin disrupt endothe-
lial junctions (Corada et al., 1999), leading to an increased   
migration of leukocytes into the inflamed tissue (Gotsch et al., 
1997). This suggests that the adhesive strength of VE-cadherin 
needs to be reduced during leukocyte diapedesis. We recently 
demonstrated that this is the case, as mice expressing a VE- 
cadherin--catenin  fusion  protein  instead  of VE-cadherin 
were resistant to the induction of vascular permeability in the 
skin, and leukocyte recruitment into various inflamed tissues 
was strongly reduced in these mice (Schulte et al., 2011).
One mechanism whereby the adhesiveness of VE-cadherin 
might be impaired is the tyrosine phosphorylation of the   
VE-cadherin–catenin complex. It was reported that the stim-
ulation of endothelial cells with permeability-enhancing me-
diators such as vascular endothelial growth factor (VEGF), 
histamine, or thrombin triggers tyrosine phosphorylation of 
VE-cadherin and the associated catenins (Vestweber et al., 
2009).  Similarly,  leukocytes  adhering  to  endothelial  cells 
were  shown  to  induce  tyrosine  phosphorylation  of  the 
VE-cadherin–catenin  complex  (Allingham  et  al.,  2007; 
Nottebaum et al., 2008; Turowski et al., 2008). Furthermore, 
mutating various tyrosines in the VE-cadherin cytoplasmic 
tail  resulted  in  a  decreased  transmigration  of  leukocytes 
across endothelial monolayers in vitro (Allingham et al., 2007; 
Turowski et al., 2008).
We found that the endothelial-specific vascular endo-
thelial  protein  tyrosine  phosphatase  (VE-PTP)  associates 
with VE-cadherin and enhances its adhesive function when 
coexpressed in Chinese hamster ovary cells (Nawroth et al., 
2002). Recently, we showed that VE-PTP is indeed required 
in endothelial cells for proper functioning of VE-cadherin 
(Nottebaum et al., 2008). A lack of VE-PTP in endothelial 
cells  leads  to  increased  cell  layer  permeability,  decreased   
VE-cadherin adhesive function, and increased migration of 
leukocytes  through  cultured  endothelial  cell  monolayers.   
Intriguingly, we showed that adhesion of leukocytes to cyto-
kine-activated endothelial cells, and stimulation of endothelial 
cells with VEGF, triggers the dissociation of VE-PTP from 
VE-cadherin (Nottebaum et al., 2008). This correlation sug-
gests that in situations where endothelial cell contacts have 
to be loosened, VE-PTP might need to dissociate from 
VE-cadherin to allow a modulation of the adhesive strength 
of VE-cadherin.
Here, we have analyzed whether dissociation of VE-PTP 
from VE-cadherin occurs in vivo and whether this process is 
required for the opening of endothelial junctions during 
leukocyte extravasation and induction of vascular permeability. JEM Vol. 208, No. 12  2395
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Generation of transgenic mice expressing  
VE-cadherin-FKBP and VE-PTP-FRB*  
under the endogenous VE-cadherin promoter
To test whether the dissociation of VE-PTP from VE-cadherin 
is a prerequisite for the destabilization of endothelial cell 
contacts in vivo, we generated knock-in (KI) mice express-
ing VE-cadherin-FKBP  and  full-length VE-PTP-FRB* 
specifically under the endothelial specific VE-cadherin pro-
moter. To this end, the ATG-containing exon 2 of VE-
cadherin was flanked in mouse embryonic stem (ES) cells with 
two incompatible loxP sites (Fig. 2 A). Based on recombination-
mediated cassette exchange (RMCE), these two loxP sites al-
lowed exon 2 to be replaced by any cDNA construct that was 
also flanked by such a pair of incompatible loxP sites upon 
co-transfection with the recombinase Cre. We designed a KI 
reverse  this  phosphorylation  of  VE-cadherin-FKBP  with 
similar  efficiency  as WT  Flag-VE-PTP  dephosphorylated 
WT VE-cadherin (Fig. 1 D, lanes 1 and 3). Collectively,   
we conclude that the additional FKBP and FRB* domains 
do  not  affect  the  molecular  interactions  of  VE-cadherin   
and VE-PTP.
Figure 1.  VE-cadherin-FKPB and Flag-VE-PTP-FRB* show the 
same characteristics as WT proteins. (A) Schematic illustration of VE-
cadherin-FKBP and VE-PTP-FRB* transmembrane domain (TM) and HA-
tag (HA). (B) VE-cadherin or VE-cadherin-FKBP were expressed in COS-7 
cells. VE-cadherin was immunoprecipitated, and the indicated proteins 
were detected by immunoblotting. The horizontal line indicates different 
experiments. (C) The indicated proteins were expressed in COS-7 cells, and 
Flag-VE-PTP or Flag-VE-PTP-FRB* were immunoprecipitated, followed by 
analysis for Flag-VE-PTP and co-precipitated VE-cadherin-FKBP or VE-
cadherin by immunoblotting. Expression of transfected proteins was con-
trolled by immunoblots of total cell lysates. (D) VEGFR-2 was coexpressed 
with the indicated proteins in COS-7 cells. VE-cadherin was immuno-
precipitated, followed by immunoblotting for phosphotyrosine and VE-
cadherin. Data are representative for two (B), six (C), and three (D) 
independent experiments.
Figure 2.  Generation of transgenic mice expressing VE- 
cadherin-FKBP and VE-PTP-FRB*. (A) Schematic illustration of the 
RMCE approach. The gene replacement cassette contains cDNAs for  
VE-cadherin-FKBP and full-length VE-PTP-FRB* separated by an IRES site, 
as well as a Hygromycin cassette, flanked by two FRT sites. The cassette is 
flanked by two incompatible loxP sites. Using RMCE, the ATG-containing 
exon 2 of VE-cadherin was replaced by the cDNA insertion cassette. Posi-
tions of the primers for PCR-genotyping are indicated. (B) Lung lysates of 
either wild-type (+/+), heterozygous (+/KI), or homozygous mutant (KI/KI) 
mice were immunoblotted for VE-cadherin and as loading control for Tie-2. 
(C) Endogenous VE-PTP was immunoprecipitated with anti–VE-PTP-C  
and VE-PTP-FRB* was immunoprecipitated with anti-HA antibodies from 
lung lysates of homozygous KI (KI/KI) or WT (+/+) mice. Immunoprecipita-
tions with goat IgG (CoIgG) were performed as a control. Precipitates 
were analyzed by immunoblotting with antibodies against the extracel-
lular domain of VE-PTP. Note that KI mice showed only slightly increased 
overall amounts of VE-PTP compared with WT mice (left) because the 
anti–VE-PTP-C antibodies bind to VE-PTP-FRB* only very weakly.  
(D) Whole mount staining of venules in cremaster from WT mice (left)  
and KI mice (right) for VE-cadherin or VE-cadherin-FKBP, respectively. 
Bars, 20 µm. Data are representative for three (B and C) and two (D)  
independent experiments.2396 VE-PTP/VE-cadherin control endothelial junctions | Broermann et al.
mice to nebulized LPS for 1 h. Mice were sacrificed either im-
mediately or 1 h later, and lungs were processed as described 
for Fig. 3 A. Immunoblotting for VE-cadherin-FKBP revealed 
that its interaction with VE-PTP-FRB* was reduced by 60% 
2 h after the onset of LPS stimulation. The precipitated levels 
of VE-PTP-FRB* and the expression levels of VE-cadherin-
FKBP in the lung lysates were unchanged (Fig. 3 B).
We conclude that VEGF stimulation and stimulation of 
leukocyte extravasation by LPS leads to the dissociation of 
VE-PTP from VE-cadherin in vivo, suggesting that this dis-
sociation is indeed a physiological process that accompanies 
the opening of endothelial junctions.
construct  flanked  by  these  two  loxP  sites,  containing  the   
cDNAs of VE-cadherin-FKBP and VE-PTP-FRB* separated 
by an internal ribosome entry site (IRES; Fig. 2 A). ES-cells 
were analyzed by PCR and Southern blots confirming cor-
rect homologous recombination (Fig. S1).
The resulting KI mice were viable, fertile, and healthy. As 
documented by immunoblotting of lung lysates, endogenous 
WT VE-cadherin was no longer expressed and VE-cadherin-
FKBP was expressed at the same level as VE-cadherin in WT 
mice (Fig. 2 B). Junctional staining for VE-cadherin-FKBP 
in whole mounts of cremaster tissue was indistinguishable 
from VE-cadherin staining of WT mice (Fig. 2 D). Mobility 
and junctional recruitment of VE-cadherin and VE-cadherin-
FKBP were similar, because the adhesion-blocking antibody 
BV13 against VE-cadherin removed both proteins from junc-
tions with similar efficiency in primary isolated endothelial 
cells from lungs of WT and of KI mice (Fig. S2).
As the cDNA for VE-PTP-FRB* was inserted into the 
VE-cadherin locus, expression of endogenous WT VE-PTP 
was unaffected. Expression levels of VE-PTP-FRB* and   
endogenous WT VE-PTP were too low for direct analysis of 
lung lysates in immunoblots. The only antibody well suited 
for immunoprecipitation was one directed against the C ter-
minus (anti–VE-PTP-C), which precipitated VE-PTP well 
but bound to VE-PTP-FRB* only very weakly. To compare 
the  expression  levels  of  VE-PTP-FRB*  and  endogenous 
VE-PTP, we precipitated VE-PTP with anti–VE-PTP-C, 
and  VE-PTP-FRB*  with  an  anti–HA-tag  antibody  from 
lung lysates, followed by immunoblotting with antibodies 
that recognized both proteins equally well (Fig. 2 C). Taking 
into account the different binding efficiency of the anti–VE-
PTP-C and anti–HA-tag antibodies determined in immuno-
precipitations of transfected COS7 cells (unpublished data), 
we determined that the expression level of VE-PTP-FRB* 
was 30% of the level of endogenous WT VE-PTP. Because 
of the large molecular weight of VE-PTP (350/265 kD dou-
blet; Bäumer et al., 2006), the small FRB* domain did not 
cause a detectable molecular weight shift by SDS-PAGE.
VE-PTP dissociates from VE-cadherin in vivo after VEGF 
stimulation and induction of leukocyte extravasation
Because the dissociation of VE-PTP from VE-cadherin upon 
leukocyte  docking  or  stimulation  of  endothelial  cells  with 
VEGF had only been demonstrated in vitro (Nottebaum et al., 
2008), we tested whether this dissociation also occurs in vivo. 
KI mice were injected i.v. with 3 µg VEGF in 100 µl PBS or 
with PBS alone as a control. At 5, 15, and 30 min after the   
injections, VE-PTP FRB* was immunoprecipitated from lung 
lysates, and precipitates were analyzed for VE-cadherin-FKBP 
by immunoblotting. The amounts of VE-cadherin-FKBP co-
precipitated with VE-PTP FRB* were significantly reduced at 
15 and 30 min after VEGF treatment, whereas the precipitated 
levels of VE-PTP-FRB* were equal (Fig. 3 A).
To test whether leukocytes would induce the dissociation 
of VE-PTP FRB* from VE-cadherin-FKBP in vivo, we in-
duced pulmonary inflammation in WT mice by exposing the 
Figure 3.  Dissociation of VE-PTP FRB* from VE-cadherin-FKBP 
occurs in vivo after application of VEGF or LPS. (A) Homozygous KI 
mice received 3 µg VEGF i.v. and were sacrificed at the indicated time 
points. VE-PTP FRB* was immunoprecipitated from lung lysates and pre-
cipitates were blotted for VE-PTP and VE-cadherin. (B) KI mice were un-
treated or inhaled an LPS aerosol for 1 h (3.5 mg/7 ml). LPS-treated mice 
were sacrificed either immediately after LPS exposure or left untreated for 
an additional 1 h. Lungs were analyzed at the indicated time points after 
starting LPS treatment. Degradation of VE-cadherin was controlled by 
immunoblotting total lung lysates (bottom). Data are representative of 
three independent experiments (A and B).JEM Vol. 208, No. 12  2397
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but not of other VE-PTP substrates such as Tie-2, we treated 
the animals with VEGF and rapalog or vehicle, and immuno-
precipitates of VE-cadherin or Tie-2 from lung lysates were 
analyzed for phospho-tyrosines in immunoblots. As shown in 
Fig. 4 (B and C), the rapalog decreased tyrosine phosphoryla-
tion of VE-cadherin, -catenin and plakoglobin, but not of 
Tie-2. As an additional control, we tested whether the rapa-
log or the expression of VE-cadherin-FKBP affected the dis-
tribution of cortical actin or myosin light chain (MLC)-2 in 
primary endothelial cells isolated from lungs of the KI mice. 
As shown in Fig. S3, we found no such effects.
Because i.v. injection of VEGF did not induce plasma 
protein leakage into the alveolar space, probably because of a 
lack of effect on the alveolar epithelium, we used the Miles 
permeability assay in the skin. In this way, we tested whether 
preventing the dissociation of VE-PTP from VE-cadherin 
would impair the induction of vascular permeability by VEGF 
in vivo. We injected KI mice i.v. with 250 µg rapalog or   
vehicle 8 and 4 h before the assay. Subsequently, mice were i.v. 
injected with Evan’s blue dye and stimulated intradermally 
10 min later with VEGF or PBS. Injected skin areas were ex-
cised 30 min later, and the dye was extracted with formamide. 
Dissociation of VE-PTP from VE-cadherin is required  
for the induction of vascular permeability by VEGF
To test whether the rapalog would indeed block the VEGF-
induced dissociation of VE-cadherin-FKBP and VE-PTP-
FRB* in vivo, we injected KI mice i.v. with 250 µg rapalog 
or vehicle 8 and 4 h before the assay. Subsequently, VEGF or 
PBS was administered i.v., and 30 min later, lung lysates were 
immunoprecipitated  for  VE-PTP-FRB*.  Immunoprecipi-
tates were first blotted for VE-cadherin-FKBP, and the same 
filters were subsequently reanalyzed for VE-PTP-FRB*. In 
addition, lung lysate aliquots were set aside and analyzed 
directly by immunoblotting for VE-cadherin-FKBP, to con-
trol for degradation. As shown in Fig. 4 A, the amount of   
VE-cadherin-FKBP (standardized to the amount of precipi-
tated VE-PTP-FRB*) that was co-precipitated was reduced 
by 31% upon VEGF stimulation in the presence of vehicle, 
whereas VEGF no longer reduced the co-precipitation effi-
ciency if the mice had been treated with the rapalog. Thus, 
the  rapalog  does  inhibit  VEGF-induced  dissociation  of   
VE-PTP-FRB* from VE-cadherin-FKBP in vivo.
To assess whether the rapalog affects tyrosine phosphory-
lation of components of the VE-cadherin-catenin complex, 
Figure 4.  Dissociation of VE-PTP from VE-cadherin is necessary for VEGF-induced permeability in vivo. (A) Homozygous KI mice were in-
jected i.v. either with vehicle alone (left) or with rapalog (right) 8 and 4 h before the assay. Mice were then i.v. injected with either PBS or with VEGF 
(as indicated), and 30 min later lung lysates were immunoprecipitated for VE-PTP-FRB*. Precipitated material was analyzed by immunoblotting for  
VE-cadherin-FKBP and VE-PTP expression. To control for degradation, aliquots of total lung lysates were set aside and analyzed by immunoblotting for 
VE-cadherin-FKBP (bottom). The amount of immunoprecipitated VE-PTP-FRB and co-precipitated VE-cadherin-FKBP detected from VEGF-treated mice 
is shown as percentage of the amount precipitated from PBS-treated mice (numbers below). Graphs in inserts give co-precipitation efficiency. Note 
that the rapalog blocked dissociation of VE-cadherin from VE-PTP. (B) Homozygous KI mice were treated with rapalog or vehicle and subsequently 
with VEGF as in A. Lung lysates were immunoprecipitated for VE-cadherin and precipitates were immunoblotted first for phosphotyrosine, and then 
for VE-cadherin and plakoglobin (-catenin). (C) Lung lysates from KI mice were immunoprecipitated for Tie-2 and immunoblots were analyzed for 
phospho-tyrosine and subsequently for Tie-2. (D) Homozygous KI mice were injected i.v. with rapalog (black bars) or vehicle alone (white bars) 8 and 4 h  
before the assay. At the start of the assay, Evan’s blue was i.v. injected, followed by intradermal injection of VEGF or PBS 10 min later. After 30 min, 
mice were sacrificed and the dye was extracted from skin samples and quantified. n = 5 mice per group. Data are representative of two (A–C) or three 
(D) independent experiments. (E) Homozygous KI mice were treated with rapalog or vehicle as in D, followed by exposing the mice to nebulized LPS 
for 45 min. 4 h later, lungs were lavaged and protein content was measured. n = 3 mice per group. Results shown are representative of two indepen-
dent experiments. *, P ≤ 0.05; **, P ≤ 0.01.2398 VE-PTP/VE-cadherin control endothelial junctions | Broermann et al.
As shown in Fig. 4 D, VEGF induced a 2.5-fold increase 
in vascular permeability in vehicle-treated KI mice, whereas 
VEGF no longer induced any significant increase in per-
meability in rapalog-treated mice. No such inhibitory effect 
was seen with the rapalog in WT mice (not depicted) or in 
mice in which exon 2 of VE-cadherin had been replaced by 
the cDNA for WT VE-cadherin (Fig. S4).
Analyzing an alternative model of LPS-induced pulmo-
nary inflammation, we found that the rapalog inhibited most 
of  the  LPS-induced  plasma  protein  leak  into  the  alveolar 
space (Fig. 4 E). Thus, the dissociation of VE-PTP from   
VE-cadherin is indeed a necessary step in the molecular pro-
cess whereby VEGF or LPS stimulates vascular permeability 
in vivo.
Dissociation of VE-PTP from VE-cadherin is necessary  
for efficient leukocyte diapedesis in vivo
Next,  we  wanted  to  know  whether  the  dissociation  of   
VE-PTP from VE-cadherin is necessary for efficient leuko-
cyte diapedesis and extravasation in inflammation. To test 
this, we analyzed leukocyte extravasation by intravital micros-
copy of the IL-1-stimulated cremaster in our KI mice. The 
mice were pretreated with rapalog or vehicle as described for 
Fig. 4, and mice were intrascrotally stimulated with IL-1 
immediately after the second injection. 4 h later, the cremas-
ter muscle was analyzed by intravital microscopy. We found 
that IL-1–induced extravasation of leukocytes was reduced 
by 50% by the rapalog (Fig. 5 A), whereas neither the 
number of adhering or rolling leukocytes nor the rolling ve-
locity were significantly affected (Fig. 5, B–D). In addition, 
peripheral leukocyte counts were unaffected by the rapalog 
(unpublished data). Importantly, the rapalog had no effect on 
IL-1–induced leukocyte extravasation in WT mice (not de-
picted) or in mice in which exon 2 of VE-cadherin had been 
replaced by a WT VE-cadherin cDNA (Fig. S4).
As an additional inflammation model, we analyzed LPS-
induced acute lung injury. KI mice were exposed for 45 min 
to nebulized LPS upon rapalog administration, and 4 h later 
lungs were lavaged and infiltrated neutrophils were counted. 
As shown in Fig. 5 E, rapalog inhibited neutrophil recruit-
ment by 57%. We conclude that the dissociation of VE-PTP 
from VE-cadherin is indeed required for efficient leukocyte 
extravasation in the inflamed cremaster and the lung.
Our results demonstrate for the first time that the associa-
tion of VE-PTP with VE-cadherin stabilizes endothelial cell 
contacts in vivo. We show that LPS-induced inflammation and 
systemic stimulation with VEGF induce the dissociation of 
this  complex  in  vivo.  Preventing  this  dissociation  inhibits   
LPS- and cytokine-induced leukocyte extravasation and blocks  Figure 5.  Dissociation of VE-PTP from VE-cadherin is necessary 
for efficient transendothelial migration of leukocytes in vivo. Homo-
zygous KI mice were i.v. injected with either rapalog or vehicle alone 8 
and 4 h before the assay, followed by an intrascrotal injection of 50 ng  
IL-1. The cremaster muscle was prepared 4 h later for intravital imaging. 
Numbers of extravasated (A) and adherent leukocytes (B), rolling flux 
fraction (C), and rolling velocity (D) were determined. The results are dis-
played as mean ± SEM of at least 30 vessels from five independent ani-
mals in each group. (E) Homozygous KI mice were treated with rapalog or 
vehicle and exposed to nebulized LPS as in Fig. 4 E. The leukocytes in the 
bronchoalveolar lavage fluid were counted and the numbers of neutro-
phils were determined by FACS. n = 3 mice per group. Results shown are 
representative for two independent experiments. *, P ≤ 0.05; **, P ≤ 0.01; 
***, P ≤ 0.001.
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recombination of mouse ES cells using the targeting vector U2-HR that 
contained a 6.9-kb long arm 5 of exon 2 and the LoxP/Lox2272-flanked 
exon 2 of VE-cadherin, followed by an FRT-flanked neo cassette and a 1.5-kb 
short arm. Neomycin-resistant clones were screened by PCR and Southern 
blot analysis. For RMCE, positive clones were co-transfected with the afore-
mentioned RMCE exchange vector and a Cre recombinase expression plas-
mid. Hygromycin-resistant colonies were screened by PCR and confirmed 
by Southern blotting. Positive ES cell clones were injected into blastocysts of 
C57BL/6 mice to generate chimeras, which were mated with C57BL/6 
mice.  The  generated  mice  were  intercrossed  to  generate  homozygous   
VE-cadherin FKBP/VE-PTP FRB* mice. For controls mice were gener-
ated by inserting a VE-cadherin cDNA in the same way into the VE-
cadherin  locus.  Genotyping  was  performed  using  primers  RMCEfor 
(5-GAAGAGCTTTCGGGCTGGAATGACC-3) and RMCErev (5-GGA-
TGATATGGTAGCAGGTGTTGGGG-3), generating a 520-bp PCR prod-
uct in WT mice and a 565-bp PCR product in KI mice. Homozygous   
KI mice developed normally and were viable.
All animal experiments were approved by the Animal Care and Use Com-
mittees of the University of Münster (Germany) and the local government. 
Animals were kept in a barrier facility under special pathogen-free conditions.
Immunoprecipitation and immunoblotting. For co-immunoprecipita-
tions cells were lysed in lysis buffer containing (20 mM Imidazole, pH 6.8, 
100 mM NaCl, 2 mM CaCl2, 1% Triton X-100, 0.04% NaN3, and 1X 
Complete EDTA-free protease inhibitor cocktail [Roche]). For detection of 
phosphotyrosine after immunoprecipitation, cells were lysed in lysis buffer 
containing 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM CaCl2, 1 mM 
Na3VO4, 1% Triton X-100, 0.04% NaN3, and 1X Complete EDTA-free. 
For co-immunoprecipitations from mouse lung lysates, lungs were homoge-
nized with an Ultra Turrax (IKA-Werke) in three parts of PBS containing   
1 mM CaCl2 and 2X Complete EDTA-free protease inhibitor cocktail. Sub-
sequently, one part of 4X lysis buffer (PBS, 4% NP-40, 4 mM dithiothreitol 
[DTT], and 1 mM CaCl2) was added and incubated over night at 4°C.   
Lysates were centrifuged at 4°C for 30 min or 1 h for lung lysates at 20,000 g, 
aliquots were set aside for direct blot analysis, and aliquots for immunopre-
cipitation were incubated for 2 h at 4°C with protein A–Sepharose loaded 
with the respective antibodies. Immunocomplexes were washed five times 
with lysis buffer and analyzed by SDS-PAGE. In some cases, mice received 
an i.v. injection of 3 µg VEGF165 (PeproTech) in 100 µl PBS, or were ex-
posed for 1 h to nebulized LPS from Sigma-Aldrich (3.5 mg in 7 ml 0.9% 
NaCl) before preparation of the lung lysates. Control mice received PBS 
only. Total cell lysates, organ lysates, or immunoprecipitates were separated 
by SDS-PAGE and transferred to nitrocellulose (Schleicher & Schuell) by 
wet  blotting.  Blots  were  analyzed  as  previously  described  (Ebnet  et  al., 
2000). In some cases blots were quantified using the luminescent image 
analyzer LAS-4000 (Fuji Film) and the software MultiGauge V3.2 (Fuji 
Film). For detection of phosphotyrosine, milk powder in the blocking buffer 
was replaced by 2% BSA, and 200 µM Na3VO4 was added.
Immunofluorescence staining. Primary murine endothelial cells isolated 
from lungs were grown to confluency on laminin-coated transwell filters. 
Cells were fixed using 2% PFA/PBS. Primary antibodies were detected using 
Alexa Fluor 488– or Alexa Fluor 633–coupled secondary antibodies (Invitro-
gen). Fluorescence signals were detected using a confocal laser scanning micro-
scope (LSM 780 inverted microscope; Carl Zeiss, Inc.). Cremaster whole mount 
stainings were done as previously described (Schulte et al., 2011).
In vivo permeability assay. Mice were injected i.v. with rapalog (250 µg 
per injection) or with vehicle 8 and 4 h before the assay. Modified Miles assay 
for VEGF165-stimulated (PeproTech) vascular permeability in the skin was 
described previously (Mamluk et al., 2005). For each assay, 3 to 5 8–12-wk-
old KI and 3 to 5 sex-matched wild-type KI mice were used. In brief, Evan’s 
blue dye (Sigma-Aldrich) was injected into the tail vein (100 µl of a 1% solution 
in PBS), and 10 min later, 50 µl PBS or 100 ng mouse VEGF165 in 50 µl PBS 
was intradermally injected into the shaved back skin. 30 min later, skin areas 
VEGF-  and  LPS-induced  vascular  permeability. Thus,  we 
show here that  VE-PTP is indeed crucial for the pathophysio-
logical regulation of endothelial cell contacts in vivo.
This is the first in vivo evidence demonstrating that tyrosine 
phosphorylation of components of the VE-cadherin–catenin 
complex, or of proteins associated with this complex and within 
reach of VE-cadherin–associated VE-PTP, is an essential step 
during the opening of endothelial junctions in both processes. 
This establishes VE-PTP as an attractive target for the treatment 
of pathological vascular permeability and inflammation.
MATERIALS AND METHODS
Cell culture and reagents. COS-7 cells were cultured as described previ-
ously (Fachinger et al., 1999). Transient transfections were performed using the 
GeneJammer transfection reagent (Stratagene Europe) according to the manu-
facturer’s instructions. Cells were analyzed 24 h after transfection. Rapalog 
(AP21967) was provided by ARIAD Pharmaceuticals, Inc. Lyophilized rapalog 
was diluted in ethanol to prepare a 62.5 mg/ml stock solution. Mice were in-
jected with freshly prepared rapalog using 4% of the rapalog stock solution, 10% 
PEG-400  (Sigma-Aldrich)  in  1.7%  Tween-20  (Merck)  in  dH2O.  Primary   
endothelial cells from lungs of WT or KI mice were isolated and cultured as 
previously described (Schulte et al., 2011).
Antibodies. The following antibodies were used: pAb VE42 and mAb 11D4.1 
against mouse VE-cadherin (Gotsch et al., 1997); mAb BV-13 against mouse 
VE-cadherin (Abcam); mAb against -catenin, mAb against plakoglobin, mAb 
against -catenin and mAb against p120-catenin (all from BD); mAb 4G10 
against phosphotyrosine (Millipore); pAb PTP 1–8 against the extracellular   
fibronectin type III-like domains 1–8 of VE-PTP; pAb VE-PTP-C against   
VE-PTP (Nawroth et al., 2002); mAb 3G1 against Tie-2 (Koblizek et al., 
1997); mAb and pAb against Flag-tag (Sigma-Aldrich); pAb against HA-tag 
(Abcam); pAb against MLC-2 (Cell Signaling Technology); and Phalloidin-
Alexa Fluor 568 (Invitrogen).
Constructing  fusion  proteins.  VE-cadherin-FKBP  and  Flag-VE-PTP-
FRB* (a shortened form of VE-PTP containing an extracellular, N-terminal 
Flag-tag and the 17th FNIII-like repeat) were generated by PCR amplification 
of VE-cadherin from pCDNA3-VE-cadherin (Nottebaum et al., 2008) and 
Flag-VE-PTP were generated by PCR amplification of pFlagCMV1-VE-PTP 
(Fachinger et al., 1999) using primers containing an XbaI site. For VE-cadherin 
amplification, VE-cad-XbaI-S (5-GTATCTAGAACTGCAGTGGAGAGA-
GCC-3) and VE-cad-XbaI-AS (5-GCGTCTAGAGATGATGAGTTCC-
TCCTG-3) were used. For Flag-VE-PTP amplification, VE-PTP-XbaI-S 
(5-CGTCTAGAGAGCTCGTTTAGTGAACC-3) and PTP-XbaI-AS 
(5-CGTCTAGAATGTCTCGAGTAGATTGC-3) were used. VE-cadherin 
and Flag-VE-PTP were cloned via the XbaI sites into pC4EN-F1 and pC4-
RHE (ARIAD Pharmaceuticals, Inc). VE-cadherin-FKBP was also inserted 
into  pCDNA3-VE-cadherin  via  EcoNI,  and  HindII/EcoRV  and  Flag- 
VE-PTP-FRB* was inserted into pGeneV5HisC-VE-PTP (Nottebaum et al., 
2008) via ClaI and MfeI/BstBI.
Generation of KI mice. VE-cadherin-FKBP and full-length VE-PTP-
FRB* were expressed in mice by replacing endogenous VE-cadherin by 
cDNAs for the two fusion proteins, using RMCE. To this end, the two   
cDNAs, separated by an IRES site were cloned into a cassette exchange vector, 
by inserting VE-cadherin-FKBP into the MCS A and full-length VE-PTP-
FRB* into MCS B of the pIRES vector (Takara Bio Inc.). For subsequent 
ES cell transfection, the two cDNAs flanking the IRES site were inserted 
into the cassette exchange vector U5-3, containing a polyA transcriptional 
stop cassette and a hygromycin cassette flanked with FRT sites. The com-
plete insertion cassette was flanked by the two incompatible recombination 
sites LoxP and Lox2272. For RMCE, exon 2 of VE-cadherin containing the 
start codon was flanked with a LoxP and a Lox2272 site by homologous 2400 VE-PTP/VE-cadherin control endothelial junctions | Broermann et al.
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were excised and extracted with formamide for 5 d and the concentration of 
the dye was measured at 620 nm in a spectrophotometer (Shimadzu).
Intravital microscopy. 8 and 4 h before the assay, mice were injected with 
vehicle or rapalog (250 µg per injection). Directly after the second rapalog/
vehicle injection) mice received an intrascrotal injection of 50 ng IL-1 
(R&D Systems) in 0.3 ml of saline. 4 h later, mice were anesthetized using   
i.p. injection of 125 mg/kg ketamine hydrochloride (Sanofi), 12.5 mg/kg xyla-
zine (Tranqui Ved), and 0.025 mg/kg atropine sulfate (Fujisawa), and the 
cremaster muscle was prepared for intravital imaging as previously described 
(Zarbock et al., 2007, 2008). Intravital microscopy was performed on an up-
right microscope (Axioskop; Carl Zeiss, Inc.) with a 40 × 0.75 NA saline im-
mersion objective. Leukocyte rolling velocity, leukocyte rolling flux fraction, 
and leukocyte arrest were determined by transillumination intravital micros-
copy,  whereas  leukocyte  extravasation  was  investigated  by  reflected  light 
oblique transillumination microscopy as previously described (Mempel et al., 
2003). Recorded images were analyzed off-line using ImageJ and AxioVision 
(Carl Zeiss, Inc.) software. Leukocyte rolling flux fraction was calculated as 
percentage of total leukocyte flux. Emigrated cells were determined in an area 
reaching out 75 mm to each side of a vessel over a distance of 100-mm vessel 
length (representing 1.5 × 104 mm2 tissue area). The microcirculation was re-
corded using a digital camera (Sensicam). Postcapillary venules with a diame-
ter between 20–40 µm were investigated. Blood flow centerline velocity was 
measured using a dual-photodiode sensor system (Circusoft).
Murine model of LPS-induced pulmonary inflammation. 8 and 4 h 
before the assay, mice were vehicle or rapalog injected (125 µg per injection). 
LPS-induced pulmonary inflammation was achieved as previously described 
(Zarbock et al., 2009). In brief, LPS from 500 µg/ml Salmonella enteritidis 
(Sigma-Aldrich) was nebulized and mice were exposed for 45 min to nebu-
lized LPS or saline as a control. 4 h later, mice were sacrificed and the lungs 
were lavaged with PBS. After centrifugation, the protein concentration in the 
supernatant was determined using the BCA Protein Assay kit (Thermo Fisher 
Scientific). Leukocyte counts in the bronchoalveolar lavage fluid were ana-
lyzed and the numbers of neutrophils were determined by FACS.
Statistical analysis. Datasets were checked for normality (Shapiro-Wilk) 
and equal variance. When possible P values were determined by Student’s t 
test. Otherwise Mann-Whitney Rank Sum Test was applied. Analysis was 
done using SigmaPlot 10.0. Error bars indicate standard error of mean values.
Online supplemental material. Fig. S1 shows genotyping results for the KI 
mice and the respective ES cells. Fig. S2 shows that antibodies against VE- 
cadherin can remove VE-cadherin-FKBP as efficiently as WT VE-cadherin 
from cell contacts of primary endothelial cells from lungs of the analyzed KI 
mice. Fig. S3 shows that neither application of rapalog nor the expression of   
VE-cadherin-FKBP alters actin organization. Fig. S4 shows that the rapalog 
does not inhibit permeability induction or leukocyte recruitment in WT mice.
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